Clinical Trial Update: A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SYH2053 has been completed in hyperlipidemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• SYH2053

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Hyperlipemia | Phase 1 | Status: COMPLETED